Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach
AbstractObjective: To estimate the cost effectiveness of olanzapine and risperidone for the treatment of schizophrenia in Belgium. Methods: Data were retrieved from a prospective, observational, non-randomized, follow-up survey. Clinical investigators assigned 265 patients with schizophrenia to either olanzapine (n - 136) or risperidone (n - 129). Patients were followed up for 2 years. Total healthcare costs were determined from the public payer perspective and calculated by multiplying resource use with official tariffs; effectiveness of the drugs was measured with the EQ-5D. This study uses a net-benefit regression approach to accommodate for baseline differences between treatment groups and uncertainty. Results: Total 2-year costs were very similar for patients receiving risperidone and olanzapine (€20 915.33 and €20 569.69, respectively; p - 0.925) [year 2002 values]. The health condition of the patients receiving risperidone was better than that of patients receiving olanzapine but not significantly so (1.46 and 1.41, respectively; p - 0.191). Simple ordinary least squares (OLS) regressions indicated that, for λ - €40 000, we could not reject the null hypothesis that the drugs provide similar net monetary benefits to the patient (risperidone vs olanzapine €2046.95; p - 0.656). When we controlled for several patient characteristics, risperidone moved further away from olanzapine but the difference did not reach statistical significance (risperidone vs olanzapine €3198.07; p - 0.595). Numerous sensitivity analyses confirmed the robustness of the results. Conclusion: Results of this study suggest that it is important to control for baseline patient characteristics when performing a cost-effectiveness analysis. No significant difference in net monetary benefit was found between risperidone and olanzapine.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic InfoArticle provided by Springer Healthcare | Adis in its journal PharmacoEconomics.
Volume (Year): 27 (2009)
Issue (Month): 1 ()
Contact details of provider:
Web page: http://pharmacoeconomics.adisonline.com/
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Ifigeneia Mavranezouli, 2010. "A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States," PharmacoEconomics, Springer, vol. 28(12), pages 1109-1121, December.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.